MarketBeat
12 Jul 2026, 21:02 UTC · 9w ago
Verdict
Headline leans bearish. We score RDY −0.60 across five claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−0.60strongly bearish
What the story claims
5 claims · scored −1 bearish … +1 bullish
Dr. Reddy's will miss expected semaglutide sales for July, August, September, and October due to a scale-up impurity issue.
More negative than 96% of claims this week
The company confirmed that the impurity issue did not affect products already in the market and there are no recall concerns for semaglutide.
Continue reading
5 related stories
More negative than 82% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 76% of claims this week
Commercial supply of semaglutide injections is expected to restart in late October or early November, pending successful validation batches.
More negative than 73% of claims this week
The manufacturing issue does not affect oral semaglutide tablets or existing global regulatory filings.
More positive than 53% of claims this week
A backup API supplier is being qualified but will not be operational for approximately one year.
More negative than 63% of claims this week
Which stocks this story touches
More negative than 82% of ticker scores this week
The company is facing a scale-up issue with its semaglutide injection leading to temporary supply delays and missed sales.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
20h ago
−7.8%
Price agrees with the score
$12.15 vs $13.19 close before publication (Jul 10) · not market-adjusted
RDY chart →
